Colorectal cancer (CRC) is a noticeable reason of cancer-associated deaths with a high incidence and mortality rate. Countless effort have been put into the improving clinical management of CRC patients including more effective tools and a wide variety of biomarkers for diagnostic, prognostic or predictive purposes. In recent years, dysregulated miRNAs have been emerged as highly sensitive and specific markers to manage CRC in an effective way. They can play key roles in carcinogenesis as potential oncogenes, tumor suppressors or regulators of cancer network. Therefore, miRNAs may serve as molecular tools that can be quantified and used in diagnostic and prognostic approaches. Growing evidence also suggests that forced expression of tumor suppressor miRNAs or inhibiting the oncogene ones, can be used as a novel treatment strategy. In this review, we focus on the clinical applications of miRNAs as promising biomarkers of early cancer detection, prognosis and treatment.

结直肠癌 (CRC) 是癌症相关死亡的一个显着原因，其发病率和死亡率都很高。已为改善 CRC 患者的临床管理付出了无数努力，包括更有效的工具和用于诊断、预后或预测目的的各种生物标志物。近年来，失调的 miRNA 已成为有效管理 CRC 的高度敏感和特异性标志物。它们可以作为潜在的致癌基因、肿瘤抑制因子或癌症网络的调节因子在致癌作用中发挥关键作用。因此，miRNA 可以作为分子工具，可以量化并用于诊断和预后方法。越来越多的证据还表明，强制表达肿瘤抑制 miRNA 或抑制癌基因，可以用作一种新的治疗策略。在本次审查中，